Skip to main content

Table 1 Incidence of post-sustained virologic response (SVR) hepatocellular carcinoma (HCC) development and recurrence

From: Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals

Author (year), Reference

Major race

Country

Type of anti-HCV therapy

n

Follow-up, median, years

Male sex, n (%)

Age, median, years

Advanced fibrosis/cirrhosis, n (%)

Treatment for previous HCC

Reported HCC incidence in SVR, % (interval in years)

Annual HCC incidence in SVR, %

Reported HCC incidence in non-SVR, % (interval in years)

Annual HCC incidence in non-SVR, %

Study design

HCC development

              

Akuta (2011) [34]

Asian

Japan

IFN-based

1273

1.1

783 (61.5)

53

109 (8.6)

3.2 (5)

0.65

Retrospective

Chang (2012) [51]

Asian

Taiwan

IFN-based

1271 (including 400 non-SVR)

3.4

661 (75.9)

55.4a

355 (27.9)

1.2 (3)

0.4

Retrospective

Huang (2014) [52]

Asian

Taiwan

IFN-based

642

4.4

302 (54.3)

51.4a

86 (13.4)

5.8 (5)

1.2

Retrospective

Yamashita (2014) [53]

Asian

Japan

IFN-based

562

4.8

311 (55.3)

57

129 (23.0)

3.1 (5)

0.63

Retrospective

Oze (2014) [54]

Asian

Japan

IFN-based

1425

3.3

727 (51.0)

54.5

118 (11.6)

2.6 (5)

0.53

11.7 (5)

2.49

Prospective

Toyoda (2015) [55]

Asian

Japan

IFN-based

522

7.2

292 (55.9)

50.6

27 (5.5)

1.2 (5)

0.24

Retrospective

Wang (2016) [56]

Asian

Taiwan

IFN-based

376

7.6

185 (49.2)

54.1

127 (33.8)

1.4 (5)

0.28

Retrospective

Kobayashi (2016) [57]

Asian

Japan

IFN-based

528

7.3

308 (58.4)

54

78 (14.8)

2.2 (5)

0.44

Retrospective

El-Serag (2016) [36]

Caucasian

USA

IFN-based

10,738

2.8

10,232 (95.3)

53.1a

1548 (14.4)

0.33 (5)

0.07

Retrospective

Nagaoki (2016) [58]

Asian

Japan

IFN-based

1094

4.2

585 (53.5)

60

208 (1.9)

4.0 (5)

0.82

Retrospective

Tada (2016) [59]

Asian

Japan

IFN-based

587

14.0

324 (55.2)

50

4.4 (10)

0.45

14.7 (10)

1.59

Retrospective

Tada (2016) [60]

Asian

Japan

IFN-based

170

14.2

106 (62.4)

52.5

7.1 (10)

0.74

Retrospective

van der Meer (2016) [61]

Caucasian

Europe and Canada

IFN-based

1000

5.7

676 (68.0)

52.7

842 (85.0)

7.6 (8)

0.99

Retrospective

Kobayashi (2016) [57]

Asian

Japan

DAAs

77

4.0

34 (44.2)

63

23 (29.9)

3.0 (5)

0.62

Retrospective

HCC development or recurrence

              

Conti (2016) [39]

Caucasian

Italy

DAAs

344 (59 had previous HCC, including 30 non-SVR)

0.5

207 (60.1)

63

39 (11.3)

Resection, ablation, TACE

3.2 (0.5)d

6.3d

Retrospective

Cheung (2016) [24]

Caucasian

UK

DAAs

317 (18 had previous HCC)

1.3

NA

54

254 (80.1)

Resection, ablation, TACE

5.4 (1.3)

4.27

11.2 (1.3)

9.14

Prospective

HCC recurrence

              

Saito (2014) [62]

Asian

Japan

IFN-based

14

3.9

13 (92.9%)

72

12 (85.7)

Resection, ablation

18.0 (3)

6.62

75.3 (3)

46.61

Retrospective

Huang (2015) [63]

Asian

Taiwan

IFN-based

56

4.4

36 (64.3)

61.6

21 (37.5)

Resection, ablation

43.2b

84.8b

Retrospective

Kunimoto (2016) [64]

Asian

Japan

IFN-based

40

5.1

35 (87.5%)

65

14 (35.0)

Resection, ablation

23.0 (3)

8.71

56.0 (3)

27.37

Retrospective

Petta (2016) [65]

Caucasian

Italy

IFN-based

57

2.8

41 (72.0)

62

0

Resection, ablation

15.2 (2)

8.24

Retrospective

Minami (2016) [66]

Asian

Japan

IFN-based

38

27 (71.0)

66

0

Ablation

52.9 (2)

37.6

Retrospective

Conti (2016) [39]

Caucasian

Italy

DAAs

59 (including 6 non-SVR)

0.5

40 (67.8)

72

10 (16.9)

Resection, ablation, TACE

28.8d (0.5)

49.3d

Retrospective

Reig (2016) [40]

Caucasian

Spain

DAAs

58

0.5

40 (69.0)

66.3

5 (8.6)

Resection, ablation, TACE

27.6d (0.5)

47.6d

Retrospective

ANRS study group (2016) [42]

Caucasian

France

DAAs

189 (including 41 non-SVR)

2.2

147 (78.0)

62a

152 (80.0)

Resection, ablation, LT

0.73b,d

8.76c,d

0.66b,e

7.92c,e

Prospective

ANRS study group (2016) [42]

Caucasian

France

DAAs

13

1.8

11 (85.0)

61a

13 (100)

Resection, ablation

1.1b

13.3c

1.7b,e

20.76c,e

Prospective

ANRS study group (2016) [42]

Caucasian

France

DAAs

314

257 (82.0)

61a

49 (15.6)

LT

2.2 (0.5)

4.4

Prospective

Petta (2016) [65]

Caucasian

Italy

DAAs

58

1.5

40 (69.0)

66.3

2 (4.0)

Resection, ablation

26.3 (2)

15.3

Retrospective

Minami (2016) [66]

Asian

Japan

DAAs

27

18 (67.0)

71

0

Ablation

29.8 (2)

17.7

Retrospective

  1. When not reported, annual HCC incidence was estimated by using the declining exponential approximation of life expectancy [67]
  2. aMean
  3. b100 person-month
  4. c100 person-year
  5. dIncidence in patients including non-SVR patients
  6. eIncidence in patients not treated by anti-HCV therapy
  7. DAA direct-acting antiviral, HCC hepatocellular carcinoma, HCV hepatitis C virus, IFN interferon, LT liver transplantation, SVR sustained virologic response, TACE transarterial chemoembolization